Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Oyster Point Pharma, Inc. - common stock
(NQ:
OYST
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 30, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oyster Point Pharma, Inc. - common stock
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
December 07, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
November 08, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
November 08, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
November 07, 2022
Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development
Via
Spotlight Growth
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders
November 07, 2022
From
Halper Sadeh LLC
Via
Business Wire
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
November 07, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
November 02, 2022
Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
July 27, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
